An experimental drug being developed by Bristol-Myers Squibb Co. when used with chemotherapy appeared to keep advanced lung cancer from progressing modestly longer than chemotherapy alone, according to a summary of data from a mid-stage study. The biotechnology drug ipilimumab, which augments the body’s immune response by inhibiting certain proteins, kept advanced non-small cell lung [...]